Strategic partnerships Potential collaborations with clinics and treatment centers specializing in addiction and psychedelic-assisted therapy, leveraging Journey Colab's lead compound and late-stage trial design capabilities to expand patient access and accelerate clinical development.

Clinical leadership Opportunity to engage CMO level conversations and talent networks for advisory roles, given recent high-profile physician appointments and the importance of clinically validated approaches in psychedelic therapeutics.

Funding and grants Pursue funding channels and partnerships tied to neuroscience, mental health, and addiction care to support expansion of trials, manufacturing scale, and regulatory navigation, aligning with Journey Colab’s Series A momentum.

Technology stack fit Offer services around secure cloud infrastructure, data management, compliance tooling, and scalable web platforms to support clinical data management, patient engagement, and digital therapeutics components.

Market positioning Position as a lean, specialized psychedelic pharma partner with a focus on durable remission in AUD, highlighting neuroplasticity-based therapeutics and community-supported care to differentiate in a competitive market.